STAT+: FDA digital health leader promises generative AI regulatory guidance is coming

The Story At A Glance

• • The FDA is developing formal regulatory guidance for generative AI medical devices.


• • Rick Abramson is leading the Digital Health Center of Excellence to shape these policies.


• • Current FDA strategy focuses on risk-based oversight for software affecting diagnosis and treatment.

Context
The FDA is transitioning from broad AI oversight to specific frameworks for generative AI. This follows a discussion paper released in August 2026 regarding risk assessment and monitoring.

Christian Perspective
The use of AI in medicine must respect the biological reality of the human body and the sanctity of life. We must ensure these algorithms do not promote secular ideologies or dehumanize patients through cold, mathematical reductionism. Technology should serve to preserve life rather than replace the divine design of human biology.

Implications
Centralized control over medical AI could allow globalist entities to dictate health standards that conflict with religious liberty. There is a risk that algorithmic decision-making will prioritize efficiency over the traditional sanctity of the doctor-patient relationship. This shift could further erode individual autonomy in favor of state-sanctioned digital oversight.

Broader Trends
This movement reflects a push toward technocratic governance where algorithms replace traditional human wisdom. It aligns with a larger trend of delegating societal functions to opaque, digital systems managed by elite bureaucracies. Such shifts often serve to consolidate power within centralized administrative states.

Takeaway
Americans must demand transparency to ensure AI medical tools do not undermine biological truths or religious freedoms. We must prioritize human-centric care that honors the natural order and protects the family unit from technocratic intrusion. Support decentralized and transparent technology that serves the nation rather than globalist interests.